The growth of pharmaceutical and biological sectors determines that the industry prosperity will be further improved

After several years of adjustment and reform, the pharmaceutical industry has entered a critical period of structural adjustment According to the analysis of relevant experts, although the overall valuation of the pharmaceutical industry is relatively low at present, the favorable transmission of policy support last year has gradually highlighted the rebound of plate performance In the future, the prosperity of the industry will be improved In addition, the profitability of China's pharmaceutical industry has also improved According to the statistics of relevant data, in March this year, the cumulative income of Enterprises above the scale of pharmaceutical manufacturing industry increased by 15.80% year-on-year, 11.00% in March 2017, the total profit increased by 22.50% year-on-year, and 13.40% in March 2017 The improvement of profitability mainly benefits from the endogenous growth of pharmaceutical industry and the improvement of industry concentration In the pharmaceutical industry, the performance of the pharmaceutical biology sector has attracted attention The author understands that last year, the growth rate of China's pharmaceutical and biological industry after deducting non net profit was 14.85%, and the sub sectors such as chemical raw materials, biological products, pharmaceutical commerce and medical services outperformed the average growth rate of the industry In the quarter of 2018, after deducting non net profit, the growth rate of pharmaceutical and biological industries was 33.37%, and the average growth rate of chemical APIs and medical services was faster than that of the industry Compared with the data in recent years, it can be found that from 2009 to 2016, the sales revenue of China's medical and biological products has been increasing continuously, and maintained a rapid growth Among them, the industry's sales revenue in 2010 was 106.245 billion yuan, up 41.12% year-on-year, ranking among the growth rates in recent years In addition, the industry market scale in 2017 was 341.719 billion yuan The advantages of the pharmaceutical and biological industry are increasingly apparent, which can not be separated from the policy support and the efforts and innovation of relevant enterprises I learned that on May 15, the pharmaceutical and biological industry index opened slightly higher, and then rose strongly Industry insiders said: "the growth of pharmaceutical biology has expanded rapidly and become the leading sector in the industry Among the related concepts, innovative drugs, car-t therapy, generic drugs and other concepts have gone up, and individual stocks are active " In view of the good situation of medical and biological sectors, relevant institutions suggest that investors can focus on innovative drugs, medical devices, consumption upgrading fields, high-profile vaccines and other sectors Specifically, in terms of innovative drugs, the adjustment of drug use structure stock will bring innovative drug dividends You can focus on pharmaceutical enterprises that are "imitated into innovation", such as Hengrui pharmaceutical, Fosun Pharmaceutical, Lizhu group, etc.; you can focus on innovative pharmaceutical enterprises, such as Beida pharmaceutical, Kanghong pharmaceutical, Yifan pharmaceutical, etc.; you can also focus on innovative industrial fields, such as Wuxi pharmaceutical, Taige pharmaceutical, etc In terms of medical devices, at present, there are three logics supporting the development of the industry, i.e domestic products have the qualification of substitution; the import substitution of devices is accelerated; and the reconstruction of the valuation of innovative drugs is expected to continue to spread to innovative devices Institutions are more optimistic about the future of medical devices, and suggest to pay attention to Antu biology, Mike biology and other enterprises In the field of consumption upgrading, we can pay attention to a number of pharmaceutical enterprise brands, such as Pianzihuang, Yunnan Baiyao, guangyuyuan, dong'a Ejiao, China Resources 39, etc., among which there are enterprises in the "2018 China brand value information release list" In the field of consumption upgrading, experts say that at present, consumers pay more attention to the safety and effectiveness of drugs, and the price is relatively insensitive In this context, these brand enterprises will enjoy a premium In the vaccine sector, Zhifei biology, Watson biology and other vaccine companies also deserve the attention of investors In addition, the agency also said that in terms of biotechnology, tumor immunity has become one of the most promising directions for some agencies "We are optimistic about the car-t field which has significantly improved the therapeutic effect, because compared with the international R & D, the domestic technology starting point is not low, and even has a late development advantage in the future." One source said Overall, the growth of pharmaceutical and biological sectors is certain and will continue to increase.